0001493152-23-001628.txt : 20230117
0001493152-23-001628.hdr.sgml : 20230117
20230117163029
ACCESSION NUMBER: 0001493152-23-001628
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230112
FILED AS OF DATE: 20230117
DATE AS OF CHANGE: 20230117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nolet Chris
CENTRAL INDEX KEY: 0001782814
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32404
FILM NUMBER: 23531864
MAIL ADDRESS:
STREET 1: C/O REVANCE THERAPEUTICS, INC.
STREET 2: 7555 GATEWAY BOULEVARD
CITY: NEWARK
STATE: CA
ZIP: 94560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: POLARITYTE, INC.
CENTRAL INDEX KEY: 0001076682
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 061529524
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1960 S. 4250 WEST
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84104
BUSINESS PHONE: (385) 266-3151
MAIL ADDRESS:
STREET 1: 1960 S. 4250 WEST
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84104
FORMER COMPANY:
FORMER CONFORMED NAME: MAJESCO ENTERTAINMENT CO
DATE OF NAME CHANGE: 20050427
FORMER COMPANY:
FORMER CONFORMED NAME: MAJESCO HOLDINGS INC
DATE OF NAME CHANGE: 20040416
FORMER COMPANY:
FORMER CONFORMED NAME: CONNECTIVCORP
DATE OF NAME CHANGE: 20010815
4
1
ownership.xml
X0306
4
2023-01-12
1
0001076682
POLARITYTE, INC.
PTE
0001782814
Nolet Chris
C/O REVANCE THERAPEUTICS, INC.
7555 GATEWAY BOULEVARD
NEWARK
CA
94560
1
0
0
0
Common Stock
2023-01-12
4
M
0
36497
0
D
14403
D
Stock option (right to buy)
22.50
2023-01-12
4
M
0
3078
0.00
D
2030-04-06
Common Stock
9235
6157
D
Pursuant to the issuer's non-executive director compensation plan the reporting person was issued 50,900 Restricted Stock Units vesting in equal installments quarterly in arrears, which were previously reported on Form 4 under Table I. As of the date of the reporting person's end of service as a director on January 12, 2023, 36,497 restricted stock units that had not vested as of that date were forfeited.
The stock option was granted 04/06/2020, and reported under Table II of Form 4. The number of derivative securities and price have been adjusted to give effect to a 25-to-1 reverse stock split in May 2022. As of the date of the reporting person's end of service as a director on January 12, 2023, 3,078 stock options that had not vested as of that date were forfeited. The remaining 6,157 stock options were fully vested as of 04/06/2022, and are presently exercisable.
/s/ Chris Nolet
2023-01-17